From USFDALupin has received tentative approval for its Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 rng/1000 mg, from the United States Food and Drug Administration, to market a generic equivalent of Synjardy6 XR Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. The product will be manufactured at Lupin s Nagpur facility in India.
Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg,
12.5 mg/1000 mg, and 25 mg/1000 mg, are indicated as an adjunct to diet and exercise, to improve glycemic
control in adults with type 2 diabetes mellitus when treatment with both empaglifiozin and metformin
FDA approves Lupin s Empagliflozin, Metformin Hydrochloride ER tablets FDA approves Lupin s Empagliflozin, Metformin Hydrochloride ER tablets
07 January 2021 | News Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin hydrochloride is appropriate
Source credit: Shutterstock
Lupin Limited, a global pharmaceutical company, announced that it has received tentative approval for its Empagliflozin and Metformin Hydrochloride Extended-Release (ER) tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, from the United States Food and Drug Administration, to market a generic equivalent of Synjardy® XR tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, of Boehringer Ingelheim Pharmac
Glenmark Pharma share rises 3% after four days, here s why
Reversing from 4 days of consecutive fall, Glenmark Pharma stock opened higher at Rs 488 and gained 2.86% to hit the day s high of Rs 497.70 against the last close of Rs 483.85
BusinessToday.In | December 23, 2020 | Updated 16:07 IST
The stock has hit a 52 week high of Rs 572.70 and 52 week low of Rs 168
Glenmark Pharma shares were trading almost 3% higher on Wednesday morning after the Mumbai-based drug firm announced that its Switzerland-based unit, Glenmark Specialty S.A., entered into an exclusive licensing agreement with Menarini Group (Menarini) for Ryaltris.
The company in its press release said Glenmark Specialty has entered into an exclusive licensing agreement with the Menarini Group for commercialising its innovative nasal spray Ryaltris across 33 countries in Europe, including the Balkan region.
To embed, copy and paste the code into your website or blog:
On December 2, 2020, Boehringer Ingelheim Pharmaceuticals, Inc. (“Boehringer Ingelheim”) submitted a Citizen Petition requesting a change in the FDA’s interpretation of “strength” of biological products under the Biologics Price Competition and Innovation Act (“BPCIA”). The Citizen Petition is available on regulations.gov under docket number: FDA-2020-P-2247. Boehringer Ingelheim seeks an interpretation of “strength” to mean total drug content, without regard to concentration. The Citizen Petition further requests the FDA update its guidance documents to incorporate the new definition, and apply the updated definition to pending and approved applications before the agency.
Glenmark Pharma Shares Rise On Licensing Agreement With Menarini moneycontrol.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from moneycontrol.com Daily Mail and Mail on Sunday newspapers.